Product candidate
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Milestones
2H 2023In vivo proof-of-concept data
Cancer gene therapy
circVec
circRNA vector
2H 2023In vivo proof-of-concept data
Vaccines
2H 2023In vivo proof-of-concept data
Rare disease
Mutant KRAS1
1H 2024
Safety and immune response data
Pancreatic cancer & Multiple Myeloma TG01/QS-21 +/- anti-PD-1
Cancer Indication: Cancer gene therapy
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication: Vaccines
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication: Rare disease
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication: Pancreatic cancer & Multiple Myeloma
Combination with: TG01/QS-21 +/- anti-PD-1
Product candidate: Mutant KRAS1
Next expected event: 1H 2024
Safety and immune response data
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Two trials run and financed by collaboration partners
1Pending additional financing or partnership